Preclinical studies in non-pregnant metabolic syndrome models have shown promise; for instance, the use of anti-asprosin monoclonal antibodies has been demonstrated to improve glucose homeostasis and reduce inflammation [39]. The gene discussed is FBN1; the disease is metabolic syndrome.